Bicara Therapeutics (NASDAQ:BCAX) Shares Up 6.5% – Should You Buy?

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s share price shot up 6.5% on Friday . The stock traded as high as $15.95 and last traded at $16.4240. 24,865 shares were traded during mid-day trading, a decline of 94% from the average session volume of 396,446 shares. The stock had previously closed at $15.42.

Wall Street Analysts Forecast Growth

BCAX has been the subject of several research analyst reports. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Mizuho raised Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Citigroup initiated coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set an “outperform” rating on the stock. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $28.33.

Bicara Therapeutics Trading Up 2.6%

The firm has a market capitalization of $866.62 million, a price-to-earnings ratio of -7.04 and a beta of -0.79. The stock’s fifty day moving average price is $16.57 and its two-hundred day moving average price is $15.26.

Insiders Place Their Bets

In other news, insider David Raben sold 5,500 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $18.45, for a total value of $101,475.00. Following the transaction, the insider owned 35,497 shares in the company, valued at approximately $654,919.65. This represents a 13.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Ryan Cohlhepp sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $18.68, for a total value of $233,500.00. Following the completion of the transaction, the chief operating officer directly owned 189,141 shares of the company’s stock, valued at $3,533,153.88. This trade represents a 6.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 82,817 shares of company stock valued at $1,547,537. 15.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Bicara Therapeutics

Several large investors have recently bought and sold shares of BCAX. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Bicara Therapeutics during the fourth quarter worth about $45,000. Legal & General Group Plc increased its position in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. lifted its stake in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after buying an additional 1,474 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.